HCW Biologics Net Income From Continuing Ops Over Time
| HCWB Stock | USD 0.99 0.06 5.71% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out HCW Biologics Performance and HCW Biologics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. Market participants price HCW higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive HCW Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (16.41) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Investors evaluate HCW Biologics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating HCW Biologics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause HCW Biologics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, HCW Biologics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare HCW Biologics and related stocks such as In8bio Inc, Neurosense Therapeutics, and Adial Pharmaceuticals Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INAB | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (5.1 M) | (8.6 M) | (14.7 M) | (28.5 M) | (30 M) | (30.4 M) | (27.4 M) | (26 M) |
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (11.3 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| ADIL | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (818 K) | (420.2 K) | (1.1 M) | (11.6 M) | (8.6 M) | (10.9 M) | (19.4 M) | (12.7 M) | (9.6 M) | (13.2 M) | (11.9 M) | (12.5 M) |
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.7 M) | (12.1 M) | (12.7 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| RNAZ | (607.2 K) | (607.2 K) | (607.2 K) | (607.2 K) | (607.2 K) | (607.2 K) | (607.2 K) | (607.2 K) | (607.2 K) | (607.2 K) | (2.3 M) | (6.8 M) | (17.6 M) | (19.6 M) | (16.8 M) | (15.1 M) | (15.8 M) |
| CELZ | (28 K) | (28 K) | (28 K) | (28 K) | (28 K) | (30.8 K) | (766.1 K) | (2.7 M) | (13.7 M) | (8.5 M) | (36.3 M) | 19.2 M | (10.1 M) | (9.8 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| BCDA | 19 K | 19 K | 19 K | 19 K | 234 K | (6.7 M) | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (7.9 M) | (7.2 M) | (7.5 M) |
| BCLI | 3.6 M | 3.6 M | (3.4 M) | (4.9 M) | (9.2 M) | (8.5 M) | (5 M) | (5 M) | (13.9 M) | (23.3 M) | (31.8 M) | (24.5 M) | (24.3 M) | (16.6 M) | (11.6 M) | (10.5 M) | (11 M) |
| APRE | (3.5 M) | (254 K) | (254 K) | (436.2 K) | (15.2 M) | (15.2 M) | (15.2 M) | (15.2 M) | (15.5 M) | (28.1 M) | (53.5 M) | (37.1 M) | (112.7 M) | (13.3 M) | (13 M) | (11.7 M) | (12.2 M) |
| APVO | (51.1 M) | (51.1 M) | (51.1 M) | (51.1 M) | (51.1 M) | (59.3 M) | (112.4 M) | (32.6 M) | (53.7 M) | (44.7 M) | (30.9 M) | (29.4 M) | 7 M | (17.6 M) | (24.1 M) | (27.7 M) | (29.1 M) |
HCW Biologics and related stocks such as In8bio Inc, Neurosense Therapeutics, and Adial Pharmaceuticals Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| HCW Biologics | HCWB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2929 North Commerce |
| Exchange | NASDAQ Exchange |
USD 0.99
Check out HCW Biologics Performance and HCW Biologics Correlation. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
HCW Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.